Conducting multicenter trials through the trial innovation network comprehensive consultation Authors: Daniel F Hanley, Karen Lane, Nichol McBee, Lindsay M Eyzaguirre, W Andrew Mould, Elizabeth Holthouse, Jessica F Baird, Jonathan D Casey, Consuelo H Wilkins, Salina P Waddy, Ken L Wiley, Sara Hassani, Meghan Hildreth, Angeline Nanni, Terri L Edwards, Dixie D Thompson, Mary Stroud, Emily Serdoz, Nan Kennedy, Sarah J Nelson, Michelle Jones, Leslie R Boone, Colleen Lawrence, Sarah K Cook, Tiffany Chen, Jodie Cohen, Natalie Dilts, Alex C Cheng, Randall W Grout, Edgar R Miller, James F Casella, Daniel K Benjamin, Harry P Selker, Marisha E Palm, Lori Poole, Jeri S Burr, Daniel E Ford, Gordon R Bernard, Paul A Harris Published: 2026 ABSTRACT AbstractEffective design and execution of multicenter clinical trials remain critical yet challenging for advancing clinical care. The Trial Innovation Network (TIN) Comprehensive Consultation process was established to improve the feasibility and success of investigator-initiated trial proposals by offering structured, multidisciplinary support across 60+ Clinical and Translational Science Award (CTSA) institutions. We report outcomes from 75 trial proposals that underwent Comprehensive Consultation between 2016 and 2024. The process follows a phased Assess–Design–Compose model that integrates expertise in trial design, operations, recruitment, and informatics to generate robust, fundable grant applications. Here we demonstrate 66% of our submitted grants receive funding. This consultation framework demonstrates a scalable, high-impact approach to enhancing the rigor, efficiency, and success of multicenter clinical trials and offers a model for national and global networks seeking to improve clinical research translation.Keywords: Clinical trials, Informative research, Medicine, Trial innovation network, Research ethics Introduction Well-planned, informative multicenter clinical trials are essential for advancing clinical practice. An effective trial design that includes a prospectively defined analysis plan targeting an important clinical question, adequate resources, and community equipoise can drive feasibility and produce meaningful, generalizable results [1]. Too often, one or more of these conditions are overlooked, and trial proposals fail scientific review. Historically, the success rate for new NIH research project grant awards, including trials, has been low, ranging from 20.7% in 2022 to 21.3% in 2023 [2]. The Trial Innovation Network (TIN) Comprehensive Consultation process was established in 2016 to address common barriers to multicenter proposal development and execution, accelerating findings into clinical practice [1,3-5]. This research letter describes the TIN Comprehensive Consultation process, which draws on interdisciplinary teams of experts and a network of 60+ Clinical and Translational Science Award (CTSA) institutions to develop study proposals, into innovative, rigorous grant applications and eventual high-quality clinical trials. Methods In order to initiate a Comprehensive Consultation, consultees submit a proposal intake form to the TIN for advice and collaboration and undergo an Initial Consultation [6]. Consultees are investigators who are seeking expert advice and resources for multicenter clinical trial study design including developing proposals into protocols, enhancing study operations, and improving recruitment and retention. Consultees can range from post-doctoral fellows to professors at institutions of varying funding levels [7]. After the Initial Consultation, the consultee can then choose to proceed with developing a comprehensive proposal in partnership with the TIN. Each Initial Consultation must reach consensus approval from a TIN committee called the Proposal Assessment Team (PAT), and investigators (consultees) must wish to engage the operational support of the TIN, then a Comprehensive Consultation is initiated to plan a trial. Notably, approval from the PAT reflects an assessment of project readiness, feasibility, and alignment with TIN capabilities, rather than a determination of scientific quality or likelihood of funding. The Comprehensive Consultation leverages the expertise of Trial Innovation Centers (TICs) and a Recruitment Innovation Center (RIC) [8] to strengthen trial design, including primary hypothesis, feasibility, recruitment and retention planning, statistical analysis, clinical, data management, operational plans, and results reporting. The Comprehensive Consultation follows an Assess-Design-Compose approach (Fig. 1). During the Assess Phase, investigators meet with TIC/RIC experts to consider trial design needs for an informative trial, identify funding, and agree on solutions to enhance trial informativeness around the requirements of a trial sponsor for trial design and conduct. The Design Phase focuses on best-practice deliverables, such as the study protocol, statistical analysis plan, budget, timelines, and recruitment and retention strategy. The process leverages the CTSA's national network of resources, and electronic health record (EHR) data to inform study design, and plan outreach to potential TIN sites for selection. TIN innovations are embedded into trial design and operations [5,9-11]. Each consultation is evaluated in all planning domains. In the Compose Phase, deliverables become the foundational blocks of a grant proposal, incorporating innovative and impactful multicenter trial elements as well as RIC/TIC expert recommendations and tools into a final application for submission. Workflow of the Comprehensive Consultation Process. During the comprehensive consultation, the TIN Consultation Team and the Study Team work together to assess, design, operate, and ultimately submit a compelling grant proposal. Throughout the process, the multidisciplinary consultation team—including subject matter experts, trial operation experts, and biostatisticians—work collaboratively with the study team, ensuring that a trial is clinically important, well-supported, and methodologically rigorous. Results From October 26, 2016, to June 1, 2024, 75 of the 432 Initial Consultations advanced to a Comprehensive Consultation (Fig. 2). Forty-one (55%) Comprehensive Consultations resulted in grant submissions, averaging 333 days from PAT approval to grant submission (Fig. 3). Of the 41 grant submissions, 27 (66%) were funded, of which 22 trials have utilized TIN coordinating centers as partnerships or engaged CTSA institutions as sites. Of the 75 total Comprehensive Consultations, 48 (64%) did not result in a funded grant. This includes 34 consultations (45%) that did not progress to submission at the time and 14 (19%) where an application was submitted but not funded at the time. Among the consultations that did not progress to submission, half remain in active Comprehensive Consultation, while the other 17 were discontinued due to factors such as challenges completing required pilot work, regulatory or logistical barriers related to obtaining biologics or meeting FDA requirements, investigator transitions, or external sponsorship issues beyond the TIN's scope. Of the 14 consultations that did lead to a grant submission but not funding, three applications are still under review. The remaining 11 were not awarded, primarily due to budget misalignment with study aims or feasibility concerns related to operational complexity or tight submission timelines. Results of the Comprehensive Consultation Process. Between October 2016 and June 2024, 432 proposals were assigned to a TIC/RIC for an initial consultation. The initial consultations resulted in either a comprehensive consultation, recommendations report only, resources only, or are active or on hold. Each of the seventy-five comprehensive consultations completed, received recommendations for each consultation. The comprehensive consultations resulted in various outcomes, including grant submission, consultations still in progress, or the consultation did not lead to a grant submission due to a sponsorship challenge outside the TIN’s scope, or the PI decided to not move forward without further preparation. Box-and-Whisker Plot of the Consultation Timeline Metrics. Interval times in the Consultation process for the 41 grants that were submitted through the TIN. PAT approval to Grant submission, which includes the Comprehensive Consultation, and any necessary grant resubmissions, took an average of 333 days. The X on the box plots indicates the average. Discussion The TIN Comprehensive Consultation process facilitates the timely development of high-quality grant applications for the implementation of multicenter clinical trials within the CTSA consortium. Our data demonstrate a funding success rate of 66%, higher than the NIH success rate of research project grant applications received by the NIH in 2023 [1]. On average, the duration of the Comprehensive Consultation among TIN consultees was approximately 333 days. This includes delays such as timing requirements for primary grant submission, resubmissions at subsequent funding cycles, as well as other common and necessary delays inherent to the extramural funding process. These delays include waiting for sponsor-defined submission windows, responding to reviewer feedback, and, in some cases, changes in funding sponsor or funding mechanism as projects evolve or as investigators identify more appropriate opportunities. Compliance with sponsor evaluation processes reflect the TIN's commitment to partnering with consultees to develop well-designed, multicenter clinical trials. These consultations use a structured, phased approach, and leverage experienced, nationwide resources so that investigators at any stage in their career can receive targeted, fully considered support for informative trial design and innovative operational execution at no cost to the consultee. Comprehensive Consultations have impactful and meritorious trials [12,13], embedding valuable innovations by the TIN [5,10,11]. The TIN Comprehensive Consultation model demonstrates a scalable, collaborative multi-institutional framework for enhancing the rigor and success of investigator-initiated multicenter trials. CTSAs and TIN provide a solution for more informative trials and generate new evidence to improve patient health. Acknowledgements We acknowledge and are especially grateful for contributions of previous Trial Innovation Network members from Duke University, University of Utah, and Tufts University who helped develop the Comprehensive Consultation structure. We are also grateful for the partnership and engagement of the Hub Liaison teams from across the Clinical and Translational Science Award program hubs. We acknowledge and thank the NCATs program staff, principal investigator (PI) advisors, Clinical and Translational Science Award PIs, and investigative teams that have collaborated with the Trial Innovation Network. We acknowledge David Borland and staff at RENCI for housing our team science data. We acknowledge with appreciation the Vanderbilt University Medical Center Recruitment Innovation Center Community Advisory Board for their many contributions to the work of the TIN. Funding This work is supported by the National Institutes of Health Center for Advancing Translational Sciences (NCATS) and the National Institute on Aging, in support of the Trial Innovation Network under grant numbers U24TR004432 (VUMC RIC), U24TR004437 (VUMC TIC), and U24TR004440 (JHU TIC). Declaration of competing interest Dr. Wilkins reported receiving grants from Patient Centered Outcomes Research Institute during the conduct of the study. Dr. Casey reported receiving a travel grant from Fisher and Paykel Travel to speak at a conference outside the submitted work. Dr. Ford reported receiving grants from Johns Hopkins University School of Medicine during the conduct of the study. Dr. Cheng reports research funding from IDTS Medical and Metis Foundation, a consultancy with Research Triangle Institute International, and honorarium from Frontier Science Foundation, all outside the submitted work. Dr. Casella reported grants from the US Centers for Disease Control and Prevention, Maternal and Child Health Bureau, and the state of Maryland and having a patent for a panel of biomarkers for detection of brain injury with royalties paid from ImmunArray and a patent for aptamers for treatment of sickle cell disease issued outside the submitted work. Dr. Benjamin reported receiving personal fees from AbbVie, PPD, and Syneos Health outside the submitted work. Dr. Hanley reported receiving stock options from Epiwatch during the conduct of the study. All other authors declare no competing interests. Footnotes CRediT authorship contribution statement Daniel F. Hanley: Data curation. Karen Lane: Writing – review & editing, Writing – original draft, Funding acquisition. Nichol McBee: Writing – review & editing, Funding acquisition. Lindsay M. Eyzaguirre: Writing – review & editing, Methodology, Funding acquisition, Data curation. W. Andrew Mould: Methodology, Funding acquisition, Data curation. Elizabeth Holthouse: Writing – review & editing, Writing – original draft, Data curation. Jessica F. Baird: Writing – review & editing, Writing – original draft, Methodology, Data curation. Jonathan D. Casey: Writing – review & editing, Conceptualization. Consuelo H. Wilkins: Writing – review & editing, Conceptualization. Salina P. Waddy: Writing – review & editing, Conceptualization. Ken L. Wiley: Writing – review & editing, Conceptualization. Sara Hassani: Writing – review & editing, Conceptualization. Meghan Hildreth: Data curation, Conceptualization. Angeline Nanni: Data curation, Conceptualization. Terri L. Edwards: Writing – review & editing, Funding acquisition, Data curation, Conceptualization. Dixie D. Thompson: Writing – review & editing, Writing – original draft, Funding acquisition. Mary Stroud: Writing – review & editing, Funding acquisition, Conceptualization. Emily Serdoz: Writing – review & editing, Funding acquisition, Data curation, Conceptualization. Nan Kennedy: Writing – review & editing, Funding acquisition, Data curation. Sarah J. Nelson: Writing – review & editing, Data curation. Michelle Jones: Funding acquisition, Data curation. Leslie R. Boone: Writing – review & editing, Funding acquisition, Conceptualization. Colleen Lawrence: Funding acquisition, Data curation. Sarah K. Cook: Funding acquisition, Data curation. Tiffany Chen: Data curation. Jodie Cohen: Writing – review & editing, Data curation. Natalie Dilts: Writing – review & editing, Data curation. Alex C. Cheng: Data curation. Randall W. Grout: Funding acquisition, Data curation. Edgar R. Miller: Funding acquisition, Data curation. James F. Casella: Writing – review & editing, Data curation. Harry P. Selker: Data curation. Marisha E. Palm: Data curation, Conceptualization. Lori Poole: Data curation, Conceptualization. Jeri S. Burr: Writing – review & editing, Data curation, Conceptualization. Daniel E. Ford: Conceptualization. Gordon R. Bernard: Writing – review & editing, Conceptualization. Paul A. Harris: Writing – review & editing, Conceptualization. Data availability The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request. References Associated Data Data Availability Statement The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.